Expert Review of Hematology最新文献_第3页

Comprehensive review of morphological diagnosis of adult T-cell leukemia-lymphoma. 成人t细胞白血病淋巴瘤形态学诊断综述。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-10 DOI: 10.1080/17474086.2025.2490759

Shigeo Fuji, Masakazu Muta, Tomoko Hisakata, Noriaki Kawano, Eiichirou Ikeda, Hiroyoshi Kouno, Yuya Tanabe, Kayoko Nakanishi

{"title":"Comprehensive review of morphological diagnosis of adult T-cell leukemia-lymphoma.","authors":"Shigeo Fuji, Masakazu Muta, Tomoko Hisakata, Noriaki Kawano, Eiichirou Ikeda, Hiroyoshi Kouno, Yuya Tanabe, Kayoko Nakanishi","doi":"10.1080/17474086.2025.2490759","DOIUrl":"10.1080/17474086.2025.2490759","url":null,"abstract":"Introduction: Adult T-cell leukemia-lymphoma (ATL) is a rare hematological malignancy associated with human T-cell leukemia virus type 1 (HTLV-1) infection. Accurate diagnosis and classification of ATL clinical subtypes rely on the identification of abnormal lymphocytes in peripheral blood smears. However, the diverse morphology of ATL cells and lack of standardized evaluation criteria worldwide can pose challenges.Area covered: This review consolidates expert opinions from clinical laboratory technologists experienced in the diagnosis of ATL. Here, we present the characteristic features of ATL cells and the common pitfalls encountered in clinical practice. In acute-type ATL, the 'flower cell' with its deeply lobulated, petal-like nucleus is a hallmark feature. While highly diagnostic, flower cells may not be abundant in all samples, and cells with minimal nuclear atypia can coexist. Chronic-type ATL is often characterized by small ATL cells with nuclear indentations or twists and hyperchromatic chromatin. Smoldering-type ATL cells share a similar morphology but generally exhibit milder nuclear atypia.Expert opinion: This review would facilitate the identification of ATL cells in routine clinical practice and serves as a foundation for future discussion and standardization of morphological criteria for ATL diagnosis.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"301-307"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What are the therapeutic options for previously treated myelofibrosis? 对于曾接受过治疗的骨髓纤维化，有哪些治疗方案？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2024-11-04 DOI: 10.1080/17474086.2024.2423367

Cassandre Petit, Hugues de Lavallade, Claire Harrison

{"title":"What are the therapeutic options for previously treated myelofibrosis?","authors":"Cassandre Petit, Hugues de Lavallade, Claire Harrison","doi":"10.1080/17474086.2024.2423367","DOIUrl":"10.1080/17474086.2024.2423367","url":null,"abstract":"Introduction: The disruption of the JAK/STAT signaling pathway is a defining feature of myelofibrosis (MF). The introduction of JAK inhibitors (JAKi) has transformed the therapeutic approach to MF, becoming essential to treatment and reshaping the management landscape. While JAKi are now the preferred first-line treatment for most patients, various management options are available for those who do not respond to initial therapy.Areas covered: This review focuses on management options for patients with MF, with particular emphasis on therapeutic strategies following the failure of first-line JAKi. It provides a comprehensive overview of the current treatment landscape, including alternative JAKi and other approaches. The review is based on an extensive literature search using available databases (PubMed, Cochrane …) and relevant web resources (clinicaltrials.gov).Expert opinion: Ruxolitinib benefits in MF often diminish after 3-4 years, with complications like thrombocytopenia and anemia. Three newer JAKi offer alternatives with similar efficacy and varied side effects. Stem cell transplantation is a curative option for a minority, ideally timed at peak response to JAKi. Research aims to enhance first-line treatments and restore responses in resistant patients. Future therapies may include novel combinations or immunotherapies targeting specific mutations, requiring collaboration between patient, clinical, and pharmaceutical communities.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"387-398"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical study on the prevention of deep vein thrombosis in patients with external fixation of lower limb fractures using an automatic ankle pump movement ceramic moxibustion rehabilitation device. 自动踝泵运动陶瓷艾灸康复装置预防下肢骨折外固定患者深静脉血栓形成的临床研究

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-15 DOI: 10.1080/17474086.2025.2492226

Weidan Yuan, Mei Lin, Shaojuan Huang, Xin Jin, Wenhong Yu, Jinfeng Huang, He Chen

{"title":"Clinical study on the prevention of deep vein thrombosis in patients with external fixation of lower limb fractures using an automatic ankle pump movement ceramic moxibustion rehabilitation device.","authors":"Weidan Yuan, Mei Lin, Shaojuan Huang, Xin Jin, Wenhong Yu, Jinfeng Huang, He Chen","doi":"10.1080/17474086.2025.2492226","DOIUrl":"10.1080/17474086.2025.2492226","url":null,"abstract":"Background: This study aims to observe the clinical effect of an automatic ankle pump ceramic moxibustion rehabilitation device in preventing deep vein thrombosis (DVT) in patients with external fixation of lower limb fractures.Research design and methods: This prospective, single-center, double-blind randomized controlled trial included 50 patients with lower limb fractures treated between April and September 2024. Patients were randomly assigned to a control group or an observation group (n = 25 each). The control group received basic and pharmacological prophylaxis; the observation group received the same plus treatment with the ceramic moxibustion device. DVT incidence, coagulation function, limb circumference, femoral vein blood flow velocity, and activities of daily living scores were compared before and one week after intervention.Results: The DVT incidence was significantly lower in the observation group than in the control group (p < 0.05). After one week, PT and APTT were higher, while D-Dimer and fibrinogen levels were lower in the observation group. Limb circumference differences, especially between affected and unaffected sides, were smaller, femoral vein flow velocity was higher, and ADL scores were significantly improved (p < 0.05).Conclusions: The device effectively prevents DVT, improves coagulation parameters and blood flow, reduces limb swelling, and enhances functional recovery.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"417-423"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients. 口服地西他滨治疗急性髓性白血病：评估老年患者的疗效、安全性和未来意义。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-02 DOI: 10.1080/17474086.2025.2487605

Pasquale Niscola

{"title":"Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients.","authors":"Pasquale Niscola","doi":"10.1080/17474086.2025.2487605","DOIUrl":"10.1080/17474086.2025.2487605","url":null,"abstract":"Introduction: Older patients with acute myeloid leukemia (AML) are often unsuitable for standard treatments and traditionally have a dismal prognosis. For 20 years, hypomethylating agents (HMAs), as single agents and recently as a backbone with venetoclax, have been used in this setting. The oral combination of decitabine and cedazuridine (C-DEC), which is therapeutically and pharmacologically equivalent to the intravenous (IV) formulation (IV-DEC), has expanded the therapeutic arsenal for AML, allowing for better convenience of administration. This review provides an overview of C-DEC, current clinical applications, and ongoing clinical studies, highlighting its potential role in managing AML in older patients.Areas covered: For the aim of this review, the authors searched the current English literature on C-DEC in AML patients through PubMed, using several pertinent keywords. To summarize the most recent developments as up-to-date as possible, we considered, with a few exceptions, only papers published over the last three years until March 2025.Expert opinion: Compared to IV-DEC, C-DEC provides similar therapeutic exposure and efficacy with an optional safety profile, enhanced treatment adherence, reduced treatment burden, and required healthcare facilities compared to those associated with IV-DEC, providing a precious tool to manage older and unfit AML patients.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"323-331"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathway. Circ_0035381通过调控miR-186-5p/CDCA3通路参与急性髓系白血病的进展。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-22 DOI: 10.1080/17474086.2025.2484377

Jinhuan Xu, Xi Ming, Jiaying Wu, Wanying Liu, Yi Xiao

{"title":"Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathway.","authors":"Jinhuan Xu, Xi Ming, Jiaying Wu, Wanying Liu, Yi Xiao","doi":"10.1080/17474086.2025.2484377","DOIUrl":"10.1080/17474086.2025.2484377","url":null,"abstract":"Background: Circular RNAs (circRNAs) are involved in acute myeloid leukemia (AML) and may be useful for AML therapy. Herein, the project aimed to explore the functions and mechanisms of circ_0035381 in AML.Research design and methods: Circ_0035381, microRNA-186-5p (miR-186-5p), and cell division cycle associated 3 (CDCA3) expression were determined using quantitative real-time polymerase chain reaction (qRT-PCR) assay. Western blot assay was used to measure protein levels. 5'-ethynyl-2'-deoxyuridine (EdU) and flow cytometry were adopted to measure cell proliferation and apoptosis. Glucose consumption and lactate uptake were examined with commercial kits. The relationships between miR-186-5p and circ_0035381 or CDCA3 were validated using dual-luciferase reporter and RNA pull-down assays.Results: Circ_0035381 was increased in the AML subject and AML cell line. Circ_0035381 deficiency hindered the proliferation and glycolysis level and promoted apoptosis in the AML cell line. Circ_0035381 sponged miR-186-5p and miR-186-5p inhibition reversed the effect of circ_0035381 knockdown on AML cell progression. CDCA3 was the target gene of miR-186-5p. CDCA3 overexpression reversed circ_0035381 knockdown-mediated AML cell proliferation and glycolysis inhibition and apoptosis promotion.Conclusions: Circ_0035381 promoted AML progression by elevating CDCA3 through sponging miR-186-5p, providing some clues for the diagnosis and treatment of AML.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"425-434"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel drug combinations for newly diagnosed multiple myeloma: how can we improve on current regimens? 新诊断多发性骨髓瘤的新药物组合：我们如何改进目前的方案？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-15 DOI: 10.1080/17474086.2025.2490764

Sofía Isabel Quezada-Ramírez, Luz Del Carmen Tarín-Arzaga, Andrés Gómez-De León, David Gómez-Almaguer

{"title":"Novel drug combinations for newly diagnosed multiple myeloma: how can we improve on current regimens?","authors":"Sofía Isabel Quezada-Ramírez, Luz Del Carmen Tarín-Arzaga, Andrés Gómez-De León, David Gómez-Almaguer","doi":"10.1080/17474086.2025.2490764","DOIUrl":"10.1080/17474086.2025.2490764","url":null,"abstract":"Introduction: Multiple myeloma (MM) therapy has greatly evolved over the last decade. Immunomodulators and anti-CD38 antibodies have reshaped the therapeutic landscape. Nevertheless, relapses occur with worsening prognosis each relapse. Achieving deep responses in first-line treatment is key to reducing future disease burden.Areas covered: To advance patient outcomes, current regimens must be continuously refined through personalization, incorporation of biomarkers to guide therapy, and novel drugs. This review aims to assess existing therapies and investigate how integrating novel drug combinations and biomarker-driven approaches can improve efficacy and tolerability for newly diagnosed multiple myeloma (NDMM) patients. Meta-analysis, systematic reviews, original articles, and real-world studies were included in this review. Databases searched included PubMed, Scopus, and Google Scholar from inception until February 2025.Expert opinion: Discerning the best therapy sequence is a challenge for NDMM individuals. Minimal residual disease assessment is becoming a pivotal tool for guiding therapeutic approaches to enhance outcomes and tolerability. Emerging evidence supports early use of potent therapies - such as next-generation anti-CD38 antibodies and CELMoDs - to achieve deeper, more durable responses and possibly delay relapses. Immunotherapies like bispecific antibodies and CAR-T cells are also being explored in front-line settings, though reducing their infectious complications is still under investigation.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"359-372"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The challenges of iron chelation therapy in thalassemia: how do we overcome them? 地中海贫血铁螯合治疗的挑战：我们如何克服它们？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-08 DOI: 10.1080/17474086.2025.2489562

Lauren E Wang, Sara Muttar, Sherif M Badawy

{"title":"The challenges of iron chelation therapy in thalassemia: how do we overcome them?","authors":"Lauren E Wang, Sara Muttar, Sherif M Badawy","doi":"10.1080/17474086.2025.2489562","DOIUrl":"10.1080/17474086.2025.2489562","url":null,"abstract":"Introduction: Packed red blood cell (pRBC) transfusions are the primary treatment for thalassemia. However, chronic transfusions ultimately result in iron overload, causing heart, liver, and endocrine complications along with other comorbidities. Although iron chelation is routinely initiated to remove excess iron, adherence remains a challenge, and iron overload still contributes to significant morbidity and early mortality in thalassemia.Areas covered: We review the evidence for iron overload and its complications in thalassemia. We also assess iron chelation strategies with possible adherence challenges categorized as patient-, medication-, and system-related barriers. Evidence suggests that lower adherence rates have been associated with more endorsed barriers. Further, patient-related barriers could be internal or external, and taking a patient-centered approach is key to addressing these challenges. Choosing the right iron chelator could help overcome some medication-related barriers. Finally, insurance coverage and access to specialized centers could affect initiation of iron chelation.Expert opinion: A critical and routine assessment of adherence barriers is key to optimizing patients' adherence to iron chelation. Adherence is often a multifactorial process, and it varies over time. Shared decision making with patients and/or caregivers is an important next step to improving adherence to iron chelation, and ultimately health outcomes.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"351-357"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary. 鉴别急性淋巴细胞白血病患者谁最适合用inotuzumab ozogamicin治疗：一个简单的语言总结。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-05-20 DOI: 10.1080/17474086.2025.2493325

David I Marks, Ryan D Cassaday, Josep-Maria Ribera, Andre C Schuh, Jae H Park, Sabina Chiaretti, Matthias Stelljes

引用次数: 0

Platelet indices in preeclampsia: comparative analysis with normotensive pregnant women. 子痫前期血小板指数：与血压正常孕妇的比较分析。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-30 DOI: 10.1080/17474086.2025.2458262

Hamza Tariq, Muhammad Hamza Khan, Fnu Poombal, Muhammad Saad Khan, Minahil Mateen Ahmad, Mehreen Khalid, Umera Saleem

{"title":"Platelet indices in preeclampsia: comparative analysis with normotensive pregnant women.","authors":"Hamza Tariq, Muhammad Hamza Khan, Fnu Poombal, Muhammad Saad Khan, Minahil Mateen Ahmad, Mehreen Khalid, Umera Saleem","doi":"10.1080/17474086.2025.2458262","DOIUrl":"10.1080/17474086.2025.2458262","url":null,"abstract":"Background: To compare platelet count (PC), mean platelet volume (MPV), and platelet distribution width (PDW) between women with preeclampsia (PE) and normotensive pregnant women, and evaluate their effectiveness as predictors of PE.Research design and methods: This cross-sectional study at Nishtar Hospital, Multan, included 141 women: 74 normotensive and 67 preeclamptic. Data was collected using an automated hematology analyzer and analyzed with SPSS version 26 and ROC curves.Results: Mean age was 27.45 ± 5.18 years for cases and 28.41 ± 5.28 years for controls (p = 0.280). Gestational age was lower in the preeclamptic group (31.97 ± 4.07 weeks) compared to controls (33.92 ± 3.30 weeks) (p = 0.002). Blood pressures were higher in preeclamptic women (p < 0.001). Platelet count was lower in preeclamptic women (183.42 ± 95.69) vs. controls (256.42 ± 77.98) (p < 0.001). MPV (10.98 ± 1.55 vs. 9.79 ± 1.59, p < 0.001) and PDW (16.82 ± 5.70vs. 14.20 ± 2.40, p < 0.001) were higher in preeclamptic women. ROC analysis showed PDW had an AUC of 0.73 and MPV an AUC of 0.71.Conclusions: PDW and MPV are significantly altered in preeclamptic women and can aid in early detection, potentially enhancing management.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"135-142"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anemia and its predictors among patients on hemodialysis, at Felege Hiote Referral Hospital, Northwest Ethiopia, 2022: a retrospective cohort study. 2022年埃塞俄比亚西北部大学希奥特转诊医院血液透析患者贫血及其预测因素：一项回顾性队列研究

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-02-01 Epub Date: 2025-01-29 DOI: 10.1080/17474086.2025.2458272

Mihretie Gedfew, Addisu Getie

{"title":"Anemia and its predictors among patients on hemodialysis, at Felege Hiote Referral Hospital, Northwest Ethiopia, 2022: a retrospective cohort study.","authors":"Mihretie Gedfew, Addisu Getie","doi":"10.1080/17474086.2025.2458272","DOIUrl":"10.1080/17474086.2025.2458272","url":null,"abstract":"Background: Anemia is a critical complication among hemodialysis patients, often leading to poor outcomes. This study aimed to assess anemia prevalence and identify predictors among hemodialysis patients at Felege Hiote Referral Hospital, Northwest Ethiopia, in 2022.Research design and methods: A retrospective cohort study analyzed 410 hemodialysis patients from January 2018 to February 2022. Data was collected from medical records, entered using Epi-data Version 4.1, and analyzed with STATA Version 14. Kaplan-Meier survival curves assessed survival time, while Cox regression identified anemia predictors.Results: Of 410 patients, 66 (16.1%) developed anemia, with an incidence rate of 7.9 per 100 person-years (95% CI: 3.1-13.5). Significant predictors included female sex (IRR: 1.5, p = 0.04), rural residence (IRR: 2.5, p = 0.01), low body mass index (IRR: 1.6, p = 0.02), and congestive heart failure (IRR: 6.9, p = 0.02).Conclusions: Anemia prevalence among hemodialysis patients is high, with key predictors including gender, residence, body mass index, and comorbidities. Interventions targeting these factors, especially in rural areas, could reduce anemia incidence. Study limitations include single-center data, incomplete variables, and lack of causality.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"143-153"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0